Grifols SA said adjusted group profit for full year 2017 rose 5.9% year over year to €660.2 million from €623.3 million.
Adjusted EBITDA saw a 14.4% year-over-year rise to €1.31 billion from €1.14 billion.
The Spanish company, which produces plasma-derived medicines, said reported group profit totaled €662.7 million, or 97 cents per share, up 21.5% from the year-ago €545.5 million, or 80 cents per share.
Net revenue amounted to €4.32 billion, a year-over-year increase of 6.6% from €4.05 billion.
The company's bioscience division recorded €3.43 billion in revenues in 2017, up from €3.20 billion a year ago. Revenues from the diagnostic division reached €732.4 million, up from €691.7 million in 2016.
Grifols booked research and development net investment of €266.3 million during the year, up 21.0% from €220.0 million a year earlier.
